Loading…
Based on limited metadata, this Warning Letter was issued to American Fertility Medical Center's Genetic Infertility & Andrology Lab on April 2, 2020, regarding biologics products or services. Without access to the full letter text or subject line details, the specific nature of the violations cannot be determined from the available information. The FDA's action indicates regulatory concerns related to biological products within the fertility and genetic testing sector, though the exact compliance issues and scope of violations remain unclear from this metadata alone.